Medical sector’s Revance Therapeutics’s (NASDAQ:RVNC) Buy rating Reiterated by Mizuho – 2 stars

Revance Therapeutics (NASDAQ:RVNC)‘s stock had its Buy rating Reiterated by analysts at Mizuho – 2 stars in a research report issued to clients and investors. A price-to-earnings ratio of #N/A, market cap of 1.7B and a beta of 1.21.  Revance Therapeutics has a twelve month low $19.51 of  and a twelve month high of $33.83.

Shares of Revance Therapeutics traded up $2.63 on Wednesday, reaching $23.08. 208,605 shares of the stock traded hands, compared to its average volume of 501639. Shares of Revance Therapeutics at close on Wednesday were at $23.08. The firm’s 50 day moving average is $27.1 and its 200 day moving average is 28.22.Revance Therapeutics  has a 12 month low of $22.23 and a 12 month high of $33.83. While on yearly highs and lows, Revance Therapeutics’s today has traded high as $23.94 and has touched $22.23 on the downward trend. See More Analyst Rating at: RATING

Revance Therapeutics (NASDAQ:RVNC) Moving Average Technical Analysis

5 day Moving Average is 24.84 And 5 day price change is -2.6 (-10.12%)  with average volume for 5 day average is 1,805,540. While technical analysis for average 20 days shows significant difference, 20 day moving average is  27.06 and 20 day price change is -3.44 (-12.97%) and average 20 day moving volume is 798,150. 50 day moving average is 27.1  and 50 day price change is -7.07 ( -23.45%)  and with average volume for 50 days is : 540,152. 200 day moving average is 28.22  and 200 day price change is -4.78 (-17.16%)  and with average volume for 200 days is : 453,351.

See More Analyst Rating at: RATING

Revance Therapeutics Earnings and What to expect: 

Revance Therapeutics last released its earnings results on August 5th, 2021. The biopharmaceutical company reported ($1.07) earnings per share for the quarter, topping the consensus estimate of ($1.14) by $0.07. The firm had revenue of $18.80 million for the quarter, compared to analyst estimates of $16.68 million. Revance Therapeutics has generated ($4.86) earnings per share over the last year (($4.73) diluted earnings per share). Earnings for Revance Therapeutics are expected to grow in the coming year, from ($4.45) to ($3.30) per share. Revance Therapeutics has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Monday, November 8th, 2021 based off prior year’s report dates.

Earnings for Revance Therapeutics are expected to grow in the coming year, from ($4.45) to ($3.30) per share. The P/E ratio of Revance Therapeutics is -4.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Revance Therapeutics is -4.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Revance Therapeutics has a P/B Ratio of 4.11. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Other owners latest trading in RVNC :

  • On 10/8/2021 shares held by Carnegie Capital Asset Management LLC were 8,400 which equates to market value of $0.23M and appx 0.00% owners of RVNC
  • On 9/3/2021 shares held by Parametric Portfolio Associates LLC were 268,401 which equates to market value of $7.96M and appx 0.00% owners of RVNC
  • On 8/17/2021 shares held by Walleye Capital LLC were 106,859 which equates to market value of $3.17M and appx 0.10% owners of RVNC
  • In total Institutional ownership equates to Institutional Ownership Percentage: 75.29% for RVNC

See More Analyst Rating at: RATING